The impact of bariatric and metabolic surgery on cancer development

Fabian Lunger; Pauline Aeschbacher; Philipp C Nett; Georgios Peros

doi:10.3389/fsurg.2022.918272

The impact of bariatric and metabolic surgery on cancer development

Front Surg. 2022 Jul 15:9:918272. doi: 10.3389/fsurg.2022.918272. eCollection 2022.

Authors

Fabian Lunger^{1

2}, Pauline Aeschbacher¹, Philipp C Nett¹, Georgios Peros²

Affiliations

¹ Department for Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Bern, Switzerland.
² Department of Visceral and Thoracic Surgery, Cantonal Hospital of Winterthur, Winterthur, Switzerland.

Abstract

Obesity (BMI ≥ 30 kg/m²) with related comorbidities such as type 2 diabetes mellitus, cardiovascular disease, sleep apnea syndrome, and fatty liver disease is one of the most common preventable risk factors for cancer development worldwide. They are responsible for at least 40% of all newly diagnosed cancers, including colon, ovarian, uterine, breast, pancreatic, and esophageal cancer. Although various efforts are being made to reduce the incidence of obesity, its prevalence continues to spread in the Western world. Weight loss therapies such as lifestyle change, diets, drug therapies (GLP-1-receptor agonists) as well as bariatric and metabolic surgery are associated with an overall risk reduction of cancer. Therefore, these strategies should always be essential in therapeutical concepts in obese patients. This review discusses pre- and post-interventional aspects of bariatric and metabolic surgery and its potential benefit on cancer development in obese patients.

Keywords: Bariatric surgery; cancer risk; metabolic surgery; roux en y gastric bypass; sleeve gastectomy.

Publication types

Review